Navigation Links
ASTRO publishes palliative radiotherapy for bone metastases guideline
Date:2/17/2011

The American Society for Radiation Oncology (ASTRO) Clinical Affairs and Quality Committee has developed a guideline for the use of radiation therapy in treating bone metastases. The guideline will be published in the International Journal of Radiation OncologyBiologyPhysics, an official journal of ASTRO.

Bone metastases are caused when a malignant tumor spreads to the bone. They can lead to debilitating effects including pain, fractures and paralysis due to spinal cord compression. The care of these patients requires collaboration between several types of cancer treatment specialists.

External beam radiation therapy (EBRT) provides successful pain relief in 50 to 80 percent of patients with little risk of side effects. However, the widespread variation in practice patterns between radiation oncologists presented an opportunity to standardize care through the construction of a formal treatment guideline.

Some of the committee's findings include:

  1. EBRT continues to be the mainstay for treating bone metastases.

  2. Both single doses and longer courses of radiation have shown similar pain relief outcomes, and each has advantages. A single course has proven more convenient for patients and caregivers, while longer courses have a lower incidence of repeat treatment to the same site.

  3. Repeat irradiation with EBRT might be feasible in some circumstances, though the details of its effectiveness and safety are still to be determined.

  4. Bisphosphonates do not eliminate the need for EBRT for painful metastases, and they act effectively when combined with EBRT.

  5. Stereotactic body radiation therapy can be considered for patients with a newly discovered or recurrent tumor in the spinal column or paraspinal areas; however, it is suggested that stereotactic treatment be reserved for patients who meet specific criteria, who are treated at centers with sufficient training and experience, and who are part of a therapeutic trial.

  6. Radionuclides are most appropriate for patients who have several sites of painful osteoblastic metastases (like those that are commonly associated with prostate cancer) that cannot be conveniently or safely treated with EBRT.

  7. Surgical decompression and stabilization plus postoperative radiation therapy should be considered for some patients with single-level spinal cord compression or spinal instability.

    Stephen Lutz, M.D., lead author of the guideline and a radiation oncologist at Blanchard Valley Regional Cancer Center in Findlay, Ohio, said, "Radiation therapy is commonly used to treat bone metastases and has been proven very effective, but with the variety of radiation therapies available and range of successful fractionation schedules, it's important to provide physicians with this guideline to assure they are using the most appropriate methods in treating patients."


    '/>"/>


Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Senate Committee Advances Disastrous Idaho Health Freedom Act
2. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
3. ASTRO awards 17 Advocacy Day travel grants
4. ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
5. Santa Monica Jury Rejects Claims of Catastrophic Brain Injury From Exposure to Mold; Plaintiff Faces Motions for Attorney Fees and Costs
6. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
7. A new endoscopic technique for gastrointestinal perforations: the over-the-scope-clip
8. ASTRO president speaks on prostate cancer at MEDCAC meeting
9. ASTRO applauds nomination of Dr. Donald Berwick to head Centers for Medicare and Medicaid Services
10. Outstanding young gastroenterologists receive AGA Foundation
11. Outstanding young gastroenterologists receive AGA Foundation 2010 Research Scholars Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... the Wharton Seminars for Business Journalists , led by the Wharton ... business and economic issues.  This one-day program at the Wharton School’s San ...
(Date:5/5/2016)... ... May 05, 2016 , ... An ... all U.S. states and certain Canadian provinces is now available from the International ... Institute (WCRI). , The report, Workers’ Compensation Laws as of January ...
(Date:5/5/2016)... Dubuque, IA (PRWEB) , ... May 05, 2016 ... ... his insurance agency’s ongoing community enrichment program serving families of greater Dubuque, IA. ... area’s active duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center ...
(Date:5/5/2016)... ... May 05, 2016 , ... Dr. Benjamin Stong of ... hair loss treatment. Dr. Stong is double board certified and the only facial ... the treatment of hair loss. Non-surgical therapies such as stem cells can be used ...
(Date:5/5/2016)... YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses Week ... job seeking nurses and healthcare employers. With their enrollment into the Talent Tech Lab ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities ... ... ... ... ...
(Date:5/3/2016)... Ore. , May 3, 2016   ... medical technology, today announced Food and Drug Administration ... resynchronization defibrillator that provides heart failure patients with ... Iperia devices also have remote monitoring with daily ... adapts the heart rate in response to physiological ...
(Date:5/3/2016)...   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month ... patients who tell their personal story and encourage those at risk to get tested and ... C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: